Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Uterine Leiomyoma (Uterine Fibroids) Overview | 8 | 1 |
| Therapeutics Development | 9 | 2 |
| Pipeline Products for Uterine Leiomyoma (Uterine Fibroids) Overview | 9 | 1 |
| Pipeline Products for Uterine Leiomyoma (Uterine Fibroids) Comparative Analysis | 10 | 1 |
| Uterine Leiomyoma (Uterine Fibroids) Therapeutics under Development by Companies | 11 | 1 |
| Uterine Leiomyoma (Uterine Fibroids) Therapeutics under Investigation by Universities/Institutes | 12 | 1 |
| Uterine Leiomyoma (Uterine Fibroids) Pipeline Products Glance | 13 | 3 |
| Late Stage Products | 13 | 1 |
| Clinical Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Uterine Leiomyoma (Uterine Fibroids) Products under Development by Companies | 16 | 1 |
| Uterine Leiomyoma (Uterine Fibroids) Products under Investigation by Universities/Institutes | 17 | 1 |
| Uterine Leiomyoma (Uterine Fibroids) Companies Involved in Therapeutics Development | 18 | 10 |
| AbbVie Inc. | 18 | 1 |
| Addex Therapeutics Ltd | 19 | 1 |
| Bayer AG | 20 | 1 |
| BioSpecifics Technologies Corp. | 21 | 1 |
| Dongkook Pharmaceutical Co., Ltd. | 22 | 1 |
| Euroscreen S.A. | 23 | 1 |
| Kissei Pharmaceutical Co., Ltd. | 24 | 1 |
| Laboratoire HRA Pharma | 25 | 1 |
| Repros Therapeutics Inc. | 26 | 1 |
| Takeda Pharmaceutical Company Limited | 27 | 1 |
| Uterine Leiomyoma (Uterine Fibroids) Therapeutics Assessment | 28 | 9 |
| Assessment by Monotherapy Products | 28 | 1 |
| Assessment by Target | 29 | 2 |
| Assessment by Mechanism of Action | 31 | 2 |
| Assessment by Route of Administration | 33 | 2 |
| Assessment by Molecule Type | 35 | 2 |
| Drug Profiles | 37 | 43 |
| collagenase clostridium histolyticum Drug Profile | 37 | 13 |
| Drug to Activate Progesterone Receptor for Uterine Fibroids Drug Profile | 50 | 1 |
| Drugs for Endometriosis and Uterine Fibroids Drug Profile | 51 | 1 |
| elagolix sodium Drug Profile | 52 | 4 |
| ESN-364 Drug Profile | 56 | 2 |
| EVE-104 Drug Profile | 58 | 1 |
| KLH-2109 Drug Profile | 59 | 1 |
| relugolix Drug Profile | 60 | 2 |
| Small Molecule to Antagonize FSH Receptor for Women's Health Drug Profile | 62 | 1 |
| Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology Drug Profile | 63 | 1 |
| telapristone acetate Drug Profile | 64 | 8 |
| triptorelin biosimilar Drug Profile | 72 | 1 |
| ulipristal acetate Drug Profile | 73 | 4 |
| vilaprisan Drug Profile | 77 | 1 |
| VPE-001 Drug Profile | 78 | 1 |
| VPEA-004 Drug Profile | 79 | 1 |
| Uterine Leiomyoma (Uterine Fibroids) Dormant Projects | 80 | 1 |
| Uterine Leiomyoma (Uterine Fibroids) Discontinued Products | 81 | 1 |
| Uterine Leiomyoma (Uterine Fibroids) Product Development Milestones | 82 | 12 |
| Featured News &Press Releases | 82 | 1 |
| May 31, 2016: BioSpecifics Technologies Announces Publication of Encouraging Data for Uterine Fibroid Treatment with CCH in American Journal of Obstetrics &Gynecology | 82 | 1 |
| May 18, 2016: Repros Reports Positive Clinical Data for Oral Proellex in Women With Severe Menstrual Bleeding Due to Uterine Fibroids | 82 | 1 |
| May 09, 2016: Allergan and Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids | 83 | 1 |
| Apr 12, 2016: Repros Reports Positive Clinical Data for Vaginal Proellex in Women With Severe Menstrual Bleeding Due to Uterine Fibroids | 84 | 1 |
| Jan 28, 2016: AbbVie Initiates Enrollment in Phase 3 Clinical Program for Elagolix in Patients with Uterine Fibroids | 85 | 1 |
| Dec 21, 2015: Repros Updates Proellex Program | 86 | 1 |
| Nov 12, 2015: Repros Therapeutics Completes Randomization of Phase 2b Study of Vaginal Proellex in Women With Symptomatic Uterine Fibroid Bleeding | 86 | 1 |
| Oct 09, 2015: Full Results of PEARL IV Study Presented at the European Society of Gynaecological Endoscopy Congress Confirms the Efficacy of Ulipristal Acetate 5 mg for the Long Term Management of Uterine Fibroids | 87 | 1 |
| Sep 16, 2015: Abbvie Announces Plans To Proceed To Phase 3 Evaluation Of Elagolix In Patients With Uterine Fibroids | 88 | 1 |
| May 28, 2015: European Commission approves Esmya 5 mg for intermittent treatment in the long term management of Uterine Fibroids (myomas) | 89 | 1 |
| Apr 21, 2015: Euroscreen starts in parallel two Phase 2 clinical trials with ESN364 in UF and PCOS patients | 90 | 1 |
| Mar 24, 2015: Bayer to present new preclinical, early clinical and epidemiological data on Vilaprisan at 62nd Annual Scientific Meeting, March 25-28, 2015, in San Francisco, CA | 90 | 1 |
| Dec 29, 2014: Repros Initiates Two Phase 2B Uterine Fibroid Studies | 91 | 1 |
| Oct 16, 2014: BioSpecifics Technologies Announces Presentation of Encouraging Preclinical Data for CCH from Collaborative Uterine Fibroid Study with Duke Medicine | 92 | 1 |
| Jun 20, 2014: Euroscreen ESN364 drug candidate presented at the ICE/ENDO Meeting | 92 | 2 |
| Appendix | 94 | 2 |
| Methodology | 94 | 1 |
| Coverage | 94 | 1 |
| Secondary Research | 94 | 1 |
| Primary Research | 94 | 1 |
| Expert Panel Validation | 94 | 1 |
| Contact Us | 94 | 1 |
| Disclaimer | 95 | 1 |